Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation
Tom Ottoboni,1 Mary Rose Keller,2 Matt Cravets,3 Neil Clendeninn,4 Barry Quart5 1Pharmaceutical and Translational Sciences, Heron Therapeutics, Inc., San Diego, CA, USA; 2Clinical Operations, Heron Therapeutics, Inc., San Diego, CA, USA; 3Biometrics, Heron Therapeutics, Inc., San Diego, CA, USA; 4C...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-03-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/bioequivalence-of-htx-019-aprepitant-iv-and-fosaprepitant-in-healthy-s-peer-reviewed-article-DDDT |